scholarly journals Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

2016 ◽  
Vol 43 (10) ◽  
pp. 1069-1079 ◽  
Author(s):  
A. Buisson ◽  
E. Vazeille ◽  
R. Minet-Quinard ◽  
M. Goutte ◽  
D. Bouvier ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Adult Patients ◽  
Faecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Reliable Marker

Tu1942 Fecal Chitinase 3-Like 1 Is a Reliable Marker As Accurate As Fecal Calprotectin in Detecting Endoscopic Activity in Adult Patients With Inflammatory Bowel Diseases

2016 ◽  
Vol 150 (4) ◽  
pp. S985
Author(s):  
Anthony Buisson ◽  
Emilie Vazeille ◽  
Regine Minet-Quinard ◽  
Marion Goutte ◽  
Damien Bouvier ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Fecal Calprotectin ◽  
Adult Patients ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Reliable Marker

scholarly journals Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases

2020 ◽  
Vol 9 (5) ◽  
pp. 1323 ◽  
Author(s):  
Lorenzo Bertani ◽  
Gian Paolo Caviglia ◽  
Luca Antonioli ◽  
Rinaldo Pellicano ◽  
Sharmila Fagoonee ◽  
...  
Keyword(s):  
Clinical Response ◽  
Inflammatory Bowel Diseases ◽  
Area Under The Curve ◽  
Clinical Role ◽  
Faecal Calprotectin ◽  
Prediction Ability ◽  
Prospective Multicentre Study ◽  
Number Of Patients ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Vedolizumab, a monoclonal antibody directed against integrin α4β7, is an effective treatment for inflammatory bowel diseases. However, a significant number of patients do not achieve steroid-free clinical remission in the first year of treatment. An early identification of these patients is one of the most important challenges for clinicians and offers the possibility of therapeutic optimization in order to personalize biological therapy. The aim of our study was to test the prediction ability of interleukin (IL)-6 and -8 of clinical response after 12 months of therapy with vedolizumab (T2). We performed a prospective, multicentre study in patients affected by inflammatory bowel disease by analysing cytokines level before starting vedolizumab (T0) and after 10 weeks of therapy (T1). In the overall cohort (n = 54), IL-8 decrease > 2.6 pg/mL in the first 10 weeks of therapy was able to predict clinical response (area under the curve (AUC) = 0.70, sensitivity = 66%, specificity = 75%, p = 0.010), negative C-reactive protein (CRP) (AUC = 0.71, sensitivity = 64%, specificity = 80%, p = 0.009) and calprotectin < 250 mg/kg (AUC = 0.69, sensitivity = 64%, specificity = 78%, p = 0.030) after 44 weeks of therapy. In patients with ulcerative colitis (n = 40), baseline IL-8 values > 8.6 pg/mL and a decrease of IL-6 values > 0.4 pg/mL from T0 to T1 were significant and independent predictors of clinical response after 12 months of vedolizumab therapy (odds ratio (OR) = 6.96, 95% CI 1.27–38.22, p = 0.026 and OR = 7.29, 95% CI 1.42–37.50, p = 0.017, respectively). In patients with Crohn’s disease (n = 14), baseline IL-8 values > 8.6 pg/mL and baseline IL-6 values > 1.6 pg/mL allowed the identification of patients achieving negative CRP at T2 (AUC = 0.75, sensitivity = 74%, specificity = 76%, p < 0.001) and patients with faecal calprotectin values < 250 mg/kg at T2 (AUC = 0.71, sensitivity = 78%, specificity = 63%, p = 0.004). In conclusion, our study highlights a potential clinical role of serum cytokine levels for the prediction of clinical and biochemical steroid-free response in patients treated with vedolizumab.

VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study

2020 ◽  
Vol 14 (11) ◽  
pp. 1512-1523
Author(s):  
Catherine Le Berre ◽  
Mathurin Flamant ◽  
Guillaume Bouguen ◽  
Laurent Siproudhis ◽  
Marie Dewitte ◽  
...  
Keyword(s):  
Internal Consistency ◽  
Inflammatory Bowel Diseases ◽  
Female Gender ◽  
Physician Global Assessment ◽  
Clinical Factors ◽  
Faecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Over Time

Abstract Background and Aims Inflammatory bowel diseases [IBD] are disabling disorders. The IBD-Disability Index [IBD-DI] was developed for quantifying disability in IBD patients but is difficult to use. The IBD-Disk is a visual adaptation of the IBD-DI. It has not been validated yet. The main objectives were to validate the IBD-Disk and to assess the clinical factors associated with a change in the score and its variability over time. Methods From May 2018 to July 2019, IBD patients from three university-affiliated hospitals responded twice to both IBD-Disk and IBD-DI at 3–12 month intervals. Validation included concurrent validity, reproducibility, and internal consistency. Mean IBD-Disk scores were compared according to clinical factors. Variability was assessed by comparing scores between baseline and follow-up visits. Results A total of 447 patients [71% Crohn’s disease, 28% ulcerative colitis] were included in the analysis at baseline and 265 at follow-up. There was a good correlation between IBD-Disk and IBD-DI [r = 0.75, p &lt;0.001]. Reproducibility was excellent [intra-class correlation coefficient = 0.90], as well as internal consistency [Cronbach’s α = 0.89]. The IBD-Disk was not influenced by IBD type but was associated with female gender and physician global assessment. Extra-intestinal manifestations, history of resection, elevated C-reactive protein and faecal calprotectin also tended to be associated with higher disability. The IBD-Disk score decreased in patients becoming inactive over time. Conclusions This study validated the IBD-Disk in a large cohort of IBD patients, demonstrating that it is a valid and reliable tool for quantifying disability for both CD and UC.

Importance of faecal calprotectin in screening and clinical assessment of adult and pediatric patients with inflammatory bowel diseases

2016 ◽  
Vol 70 (6) ◽  
pp. 480-484
Author(s):  
Ivana Čopová ◽  
Ondřej Hradský ◽  
Kristýna Zárubová ◽  
Lucie Gonsorčíková ◽  
Jiří Bronský
Keyword(s):  
Clinical Assessment ◽  
Inflammatory Bowel Diseases ◽  
Pediatric Patients ◽  
Faecal Calprotectin ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document